Successful desensitization protocol for a patient with fludarabine anaphylaxis during hematopoietic transplantation

Pediatr Allergy Immunol. 2022 Jun;33(6):e13789. doi: 10.1111/pai.13789.

Authors

Mei Xu¹, Layla AlRiyami², Harini Rao², Roxanne Hook³, Donna A Wall², Tal Schechter², Eyal Grunebaum¹

Affiliations

¹ Division of Immunology and Allergy, Department of Pediatrics, Toronto, Ontario, Canada.
² Division of Hematology and Oncology, Section of Stem Cell Transplantation, Department of Pediatrics, Toronto, Ontario, Canada.
³ Department of Pharmacy, Hospital for Sick Children, Toronto, Ontario, Canada.

PMID: 35754132
DOI: 10.1111/pai.13789

No abstract available

Keywords: anaphylaxis; desensitization; fludarabine; hematopoietic transplantation; hypersensitivity.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anaphylaxis* / diagnosis
Anaphylaxis* / etiology
Desensitization, Immunologic / methods
Drug Hypersensitivity* / diagnosis
Drug Hypersensitivity* / therapy
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Vidarabine / analogs & derivatives

Substances

Vidarabine
fludarabine